# Nanovista

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanovista

- Industry: Biotechnology
- Headquarters: Toronto, Canada
- Website: www.nanovista.ca
- Total disclosed funding: $1.8M
- Latest round: Seed (Feb 12, 2018)
- Investors on record: 1

## About

Nanovista Inc. is a Canadian company focused on developing multimodal visualization agents to enhance cancer therapy precision. Their innovative solutions target surgical and oncology applications, improving treatment outcomes for patients.Founded in 2014, Nanovista Inc. is based in Toronto, Canada, and specializes in multimodal visualization technology for cancer treatment. In February 2018, the company raised CAD 2.3 million in SEED funding from GreenSky Ventures. This funding round represents the total amount raised by the company, indicating a single investment transaction.Nanovista specializes in the development of multimodal visualization agents that are designed to enhance image-guided, high-precision cancer therapy. Their core offerings aim to improve the efficacy of surgical procedures, radiotherapy, and chemotherapy by providing real-time visualization of tumors. These agents are critical for surgeons and oncologists as they allow for better delineation of cancerous tissues during treatment, ultimately improving patient outcomes. Key end users of these products include hospitals, cancer treatment centers, and surgical clinics, catering to healthcare professionals focused on oncology. The geographical markets for Nanovista's products extend beyond the local region, targeting key international healthcare markets where advanced cancer treatment technologies are essential, such as North America, Europe, and parts of Asia.Revenue generation for Nanovista is structured around partnerships with healthcare institutions and direct sales to medical facilities that utilize their visualization agents in oncology practices. Transactions typically occur through B2B agreements, with hospitals and clinics incorporating Nanovista’s products into their treatment protocols. The company's flagship products are positioned as essential tools in the surgical and oncology landscape, facilitating a more precise approach to cancer therapy. Pricing structures are designed to align with the budgets of healthcare providers, reflecting the value of enhanced patient outcomes offered by their visualization agents. While specific pricing details are not disclosed, the cost structure typically involves direct purchasing agreements or potential subscription models for ongoing access to their technologies.Nanovista plans to leverage the CAD 2.3 million raised in SEED funding in February 2018 to further develop its product line, focusing on the creation of new visualization agents and expanding their market reach. The company aims to introduce new products by 2020 and is targeting expansion into key international markets in Europe and Asia, where there is increasing demand for advanced cancer treatment technologies. This strategic focus will enhance their ability to meet the needs of healthcare providers and improve patient outcomes.

## Funding rounds

- Seed, Feb 12, 2018, $1.8M — GreenSky Ventures

## Investors

- GreenSky Ventures (https://capitalatlas.ai/funds/greensky-ventures) — Seed